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Results:  
(Publications supported by this OTKA grant are cited in bold).  
1. Retroviral protease expression and characterization 
 To facilitate the comparative capsid and nucleocapsid cleavage specificity studies, we 
have performed specificity studies on various retroviral proteases (Eizert et al., 2008) and 
reviewed various aspects of the field (Menendez and Tözsér, 2008, Weber et al., 2009, 
Tözsér, 2010). We have also cloned HIV-2 protease (PR), but due to its self-degrading 
characteristics, stabilizing modifications of the enzyme are required (our unpublished results). 
Due to these difficulties, a triple mutant protease in which the substrate binding site residues 
of a stabilized HIV-1 PR are replaced by those differing in HIV-2 PR  appear to provide a 
solution (Tie et al., 2012). As in the period of the grant timeframe a new potential human 
retrovirus, xenotropic murine leukemia virus-related virus has been discovered; we have been 
involved in the characterization of the proteolytic enzyme of this virus (Li et al., 2011). 
Although the virus later was characterized as a product of in vitro recombination, as XMRV 
PR and Moloney murine leukemia virus (MMLV) PR appeared to have very similar 
specificity, XMRV PR characterization is expected to contribute to the better understanding 
of MMLV PR function and characteristics. An important aspect of this project was to extend 
our studies to the human T-cell lymphotropic viruses. Therefore we reviewed the field 
(Bagossi et al., 2009, Boross et al., 2009) as well as studied in detail the HTLV-1 PR, 
including its dimerization characteristics (Kádas et al., 2008) 
 
2. Study of the proteolytic processing of wild-type and mutant HIV-1 capsid proteins.  
 It has been established previously that the CA protein of HIV-1 is a substrate of the 
viral protease, although the determined cleavage sites were different in experiments using 
different techniques for identification (Tőzsér et. al., 2003; Rumlova et. al., 2003). Using an 
MS/MS-based identification, we have verified the previously found cleavage sites in CA as 
well as identified a new cleavage site between Leu43 and Ser44 (data not shown).  To make 
proteolytically resistant as well as more susceptible CA mutants, we have introduced several 
mutations into a recombinant his-tagged CA coding plasmid. The first sets of generated 
mutants are summarized in Table 1.  
 
 
 
Table 1.  Cleavage site CA mutants and the effect of mutations on the proteolytic susceptibility. 
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Mutant proteins were expressed in E. coli, purified by using nickel chelate affinity 
chromatography, then subjected to proteolytic processing by HIV-1 protease. Cleavage 
products were separated by SDS-PAGE and identified using mass spectrometry analysis of 
the cut-off bands. As the cleavage was still not completely abolished by the applied 
mutations, further multiple mutants were generated,   W23A/L43A/S44G/A77P/W117A/L189P/ 
L205A, as well as W23A/L43A/S44G/A77P/W117A/L189I/L190K/L205A. Surprisingly, while 
these mutants were substantially more resistant towards proteolysis compared to the previous 
ones, the cleavage was still not completely prevented (Figure 1), suggesting that still 
unidentified mutations exist in the CA protein.  
 
 
 
Figure 1.  Cleavage of CA mutants by HIV-1 PR. 7x-mutant: W23A/L43A/S44G/A77P/W117A/L189P/L205A,  
8x-mutant: W23A/L43A/S44G/A77P/W117A/L189I/L190K/L205A. Mutant proteins were incubated with HIV-1 
PR then the reaction mixtures were separated using SDS-PAGE. Protein bands were identified using MS and 
MS/MS techniques. 
 
 
3. Study of the effect of HIV-1 capsid  cleavage site mutations on viral infectivity.  
To be able to use a recombinant HIV-1-based lentiviral system for infectivity study, 
we modified a previously published third generation self-inactivating lentiviral system and 
utilized it to characterize trans-dominant negative HIV-1 PR inhibitor forms (Miklossy et al., 
2008). We have adopted this system to study the in vitro characterized capsid (CA) mutations 
on the infectivity of HIV-1. 293FT cells were transfected by the vectors to produce virions, 
and the supernatant of the cells was collected and concentrated with ultracentrifugation or 
ultrafiltration. The amount of viruses produced was determined by p24 ELISA assay and then 
293T cells were transduced with identical amount of p24. GFP expression of cells was 
analyzed by cytometry to compare the infectivity of the mutant virions to that of the wild 
type. 
 
Figure 2. Effect of capsid mutations on the infectivity of recombinant HIV-1 virus. (red: wild-type, green: 
proteolysis-facilitating mutations, blue: proteolysis-inhibiting mutations.)  
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Infectivity assays (Figure 2) suggested, that both enhancing and proteolysis inhibitory 
mutations caused decrease of the infectivity. To exclude the aberrant capsid structure 
formation as the cause of the reduced infectivity, CD spectra were collected for the purified 
proteins. While alteration of the secondary structures was observed in some cases, it did not 
correlate with the infectivity: for example the completely noninfectious 4x mutant had a 
secondary structure very similar to that of the wild-type protein (data not shown). We have 
also cloned and expressed HTLV-1 and MMLV CA proteins, but they did not appear to be a 
substrate of the respective protease. To study the equine infectious anemia virus (EIAV) 
capsid mutants we have developed a cell line stably expressing GFP under the viral LTR, and 
the infection of the cells can be followed by GFP expression (data not shown). 
 
4. Studies on the nucleocapsid protein processing of retroviruses.  
 While oligopeptides (EIAV NC-1 and NC-2) having the sequence of the cleavage site 
in the first and second cysteine arrays of the nucleocapsid (NC) protein of EIAV were 
previously found to be hydrolyzed by EIAV PR at the expected -Cys Tyr- and -Cys Phe- 
bonds (Tözsér et al., 1993, Figure 3). An oligopeptide representing the analogous regions 
(NC-1) was also found to be hydrolyzed by HIV-1 PR, however, cleavage occurred at the -
Phe Asn- bond instead of the predicted -Cys Phe- bond, while a peptide representing the 
region homologous to EIAV NC-2 was not hydrolyzed (Tözsér et al., 1993). Later the NC-2 
cleavage site was identified to be at the last Cys of the second zinc finger instead at the first 
one (Tözsér et al., 2004). To determine whether peptides representing the corresponding 
sequences in other retroviruses could be substrates to the respective PR, peptides having the 
corresponding sequences in AMV were assayed as substrates of the AMV PR. Although the 
generally low activity of the AMV PR (Tözsér et al., 1996) prohibited the determination of 
the exact kinetic parameters, both peptides were processed by the enzyme, at positions similar 
to those found in case of EIAV.  These data imply that cleavability of NC sequences around 
the cysteines might not be restricted to lentiviruses.  
 
 
Figure 3. Cleavage of oligopeptides having zinc finger sequences by retroviral proteinases. 
a
The Cys residues of 
the Zn finger are underlined, while the site of cleavage is indicated by an arrow.
b
Cleavage of these peptides by  
EIAV PR and their own PR have been reported previously (Tözsér et al., 1993).cThis cleavage site is at the last 
Cys residue of the second zinc finger (Tözsér et al., 2004). N.D., not determined. 
 
  OTKA K68288 
 Furthermore, we have also studied the NC cleavage of MMLV PR. The peptide 
representing the predicted cleavage site was a substrate of EIAV and AMV PRs (Figure 3), it 
was not processed by MMLV PR (data not shown). We have cloned the MMLV NC protein 
into a bacterial expression clone and studied its processing by MMLV PR. Interestingly, while 
it appeared to be a good substrate of the protease; the identified cleavage site was not in the 
zinc finger region (data not shown).  
 
5. Design of mutant NC-1 cleavage sites with various susceptibility toward proteolysis.  
 In our previous study (Tözsér et al., 2004) we have designed a limited number of NC-
1 mutants, having altered susceptibility towards HIV-1 PR. We have selected Asn17 (P1’ 
residue in the wild-type sequence) for mutagenesis, based on the following reasons: (i) 
unfavorable changes only in the P2-P2’ region of a peptide substrate could completely abolish 
hydrolysis (ii) the two cysteines (Cys15 and Cys18) are crucial for zinc coordination required 
for most of the established NC functions while Phe16 was found to be essential for the 
packaging of viral RNA. The limited set of P1’ modified substrates was extended to include 
all types of amino acid residues (Table 2). 
 
Table 2. Proteolytic processing of substituted oligopeptides representing the first cleavage site in the 
nucleocapsid protein. 
aThese values were published previously (Tözsér et al., 2004) 
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Using the recombinant viral system described for the CA mutant experiments, we have 
introduced three representative mutations into the HIV-1 NC protein of the virus and studied 
the viral infectivity. These mutations substantially reduced the infectivity of the viruses 
(Figure 4)  
 
 
 
Figure 4. Infectivity of recombinant HIV-1 virions harboring NC protein mutations. Average of two experiments 
are shown. Cells were infected with virions having equal p24 amount.  
 
 
6. Design of NC-1 cleavage revertants:  
 To verify the in vivo importance of the NC cleavage, the design and availability of 
“revertant” mutants might be very useful, in which the internal positions of the proximal zinc-
finger (CFGC motif) is not changed, nevertheless, cleavability within this region is regained 
by introducing mutations into close vicinity. The primary target positions for creation of such 
revertants should be the residues adjacent to the CFGC motif, since proper side chains in 
these positions might substitute for the loss of interaction energy caused by the mutation of 
Asn17 to Gly. Based on previous detailed specificity studies on the HIV-1 PR, we have 
selected beta branched residues or the flexible and also branched Leu as substituting residues. 
Peptides having such mutations are listed in Table 3.  
 
Table 3. Proteolytic processing of multiply substituted NC-1 cleavage site peptides. 
 
Residues substituted in the 
NC-1 cleavage site sequence are in bold, while the C-terminal arginin added to increase peptide solubility is 
underlined. 
a
Specificity constant calculated from the Km and kcat values. 
b
Specificity constant determined using a 
competition assay with RPGNF LQSRP Gag cleavage site peptide. 
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 We plan to introduce representatives of these “revertant” mutations into the NC of our 
recombinant HIV-1 virus and study the effect on viral infectivity.  
 
7. Analysis of HIV-1 particles/processing in the host cells in the early phase of the infection 
 To analyze HIV-1 particles by mass spectrometric methods, N
15
-Cys-labeled 
recombinant HIV-1 virions were produced in 293FT cells. After six passages the cells 
incorporated the heavy cysteines into their proteins. These “heavy” cells were used for 
recombinant HIV-1 virus production using our published protocol (Miklossy et al., 2008). 
The amount of the produced viruses was determined using an HIV-1 p24 antigen ELISA kit. 
The labeled viruses were used to infect 293T cells. In these experiments we planned to follow 
the fate of the viral proteins based on their heavy cysteine content. After 0, 4 and 12 hours the 
infected cells were collected and trypsinized to remove attached virions, and then cells were 
lysed in RIPA buffer in the presence of a protease inhibitor cocktail. In order to separate the 
nuclear and cytosolic fractions the Nuclei EZ prep nuclei isolation kit (Sigma) was utilized. 
The cytosolic and nuclear fractions were acetone precipitated, and then the precipitates were 
redissolved in ammonium bicarbonate and analyzed with ESI-FTICR mass spectrometer 
(Bruker). MALDI-TOF and FT-ICR mass spectrometry measurements were done but 
unfortunately, due to high PEG (polyethylene glycol) contamination the signals for the HIV-1 
particles were not unambigously visible; the PEG ionized much more efficiently and 
suppressed the protein signals. As no PEG was knowingly used in the protocol, we wanted to 
figure out its source. The provider of the nuclear fragment separation kit did not disclose the 
composition of the buffers utilized, however, MALDI-MS analysis of their lysis buffer 
verified high amount of PEG (Figure 5). At this point we plan to repeat the experiment 
avoiding the use of the isolation kit.  
 
 
 
 
 
Figure 5. Verification of PEG contamination in the buffer utilized for nuclear fraction preparation. The 44 Da 
differences are characteristic to the presence of PEG  
 
 We have also established the experimental system for MMLV infection and EIAV 
infection. 
 
8. Analysis of the host cell proteins in the early phase of the infection  
 In these experiments, non-labeled recombinant HIV-1 viruses were produced and 
quantified as described (Miklossy et. al. 2008), and utilized to infect 293T cells.  After 0, 4 
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and 12 hours the infected cells were harvested and treated as described above. Cell lysates 
were centrifuged and the supernatants were used for protein sample preparation. The cleared 
cell lysates were acetone precipitated, precipitates were redissolved in ammonium bicarbonate 
and digested with trypsin. The tryptic fragments were analyzed on an ESI-LTQ-Orbitrap 
(Thermo Scientific). The acquired MS/MS spectra were processed with Proteome Discoverer 
1.2.0. software (Thermo Scientific) and used for protein identification and also for relative 
protein quantification. For protein identification the human IPI database 
(ipi.HUMAN.v3.76_T33VStd) was used, the precursor ion mass tolerance was 10 ppm, the 
fragment ion mass tolerance was 0.5 Da. For protein quantification the areas under the curve 
of the precursor ions were used.  As a result, substantial changes were observed in the cellular 
proteome during the time-course of the infections, as exemplified in Figure 6. Analysis of the 
results is still under way. Among many others, the levels of stress proteins appear to 
substantially increase in the early phase of infection. These type proteins were previously 
found to be overexpressed in the virion-producing cells (Wheeler et al., 2007).  
 
 
 
 
 
Figure 6. Quantitative proteome changes as a consequence of HIV-1 infection. As an example, differences 
observed at 4 and 12 hours after infection are shown (only part of the results).  
 
9. Study the effect of protease inhibitors in the early-phase of viral replication 
To study the effect of protease inhibitors on the early phase of viral replication, HIV-1 
PR inhibitor saquinavir (10 µM final concentration) and UK88947 (24µM final concentration) 
were added 1 hour prior to transfection or together with the virus (Nagy et. al., 1994). Based 
on the cytometric analyses, these (very high) concentrations of inhibitors failed to inhibit 
infectivity of the virus, as exemplified with the UK88947 experiment (Figure 7). However, a 
specific EIAV PR inhibitor HBY-786 appeared to be able to significantly inhibit the GFP 
expression of our reporter cell line (data not shown).  
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B 
Fig. 7.  Effect of  UK-88947 on viral infectivity – Emission profiles (grey: control, red: wild type virus-infected 
cells, green: inhibitor treated, virus-infected cells) 
 
In another experiment, we have treated the cells with hydroxychloroquine. 
Hydroxychloroquine -being a weak base- accumulates in the organelles having low pH and 
increases the pH of these compartments. When 15 µM hydroxychloroquine was added 
together with the virus,   the infectivity of the virus was reduced by 20% (Figure 8), 
suggesting that acidification of the lysosomes may contribute to the infection of VSV-G 
pseudotyped virions. We have obtained similar results using EIAV infection of our reporter 
cell line (data not shown). To study if this acidification is related to the effect of lysosomal 
aspartic proteases, we have also treated the cells with pepstatin A, a general aspartic protease 
inhibitor. 
                        
Fig. 9.  Effect of  chloroquin on the viral infectivity (grey: control, red: wild type virus-infected cells, green: 
chroroquin-treated, virus-infected cells)  
A candidate protease to be involved in virion disassembly within the lysosomes is the 
aspartic protease Cathepsin D, which is only weakly inhibited by pepstatin A (Gacko et. al., 
2007). In our experiment pepstatin A (100 µM) added together with the virus reduced viral 
infectivity by 40%, (Figure 10), however the pretreatment of the cells one day before 
infection (data not shown).   
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Fig. 10.: effect of  pepstatin A on the viral infectivity. (grey: control, red: wild type virus-infected cells, green: 
pepstatin-treated, virus-infected cells) 
  
 Based on these results further experiments are required to clarify the effect and 
molecular targets of aspartyl protease inhibitors in the early-phase of retroviral life-cycle.  
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